Drug Index



Mechanism :

Fingolimod-phosphate, active metabolite of fingolimod, binds to sphingosine 1-phosphate receptors 1, 3, 4, and 5. Fingolimod-phosphate blocks the lymphocytes' ability to emerge from lymph nodes; therefore, the amount of lymphocytes available to the central nervous system is decreased, which reduces central inflammation.

Indication :

• Multiple sclerosis

Contraindications :

Hypersensitivity to fingolimod (including rash, urticaria, and angioedema) or any component of the formulation; MI, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or New York Heart Association (NYHA) class III/IV heart failure in the past 6 months; Mobitz Type II second- or third-degree atrioventricular (AV) block or sick sinus syndrome (unless patient has a functioning pacemaker); baseline QTc interval =500 msec; concurrent use of a class Ia or III antiarrhythmic.

Patients at increased risk for opportunistic infections, including those who are immunocompromised due to treatment (e.g., antineoplastic, immunosuppressive or immunomodulating therapies, total lymphoid irradiation or bone marrow transplantation) or disease (e.g., immunodeficiency syndrome); severe active infections including active chronic bacterial, fungal or viral infections (e.g., hepatitis, tuberculosis); known active malignancy (excluding basal cell carcinoma); severe hepatic impairment (Child-Pugh class C)

Dosing :

Children ≥10 years and Adolescents: Oral:

≤40 kg: 0.25 mg once daily.

>40 kg: 0.5 mg once OD.

Adverse Effect :

Increased gamma-glutamyl transferase, headache, diarrhea, nausea, abdominal pain, increased serum ALT and AST, influenza, neck pain, cough, sinusitis, hypertension, first and second-degree heart block, bradycardia, seizure, migraine, alopecia, hypertriglyceridemia, lymphocytopenia, herpes virus infection.

Interaction :

Antiarrhythmic Agents (Class Ia): Fingolimod may enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia).
Antiarrhythmic Agents (Class III): Fingolimod may enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III).
Beta-Blockers: May enhance the bradycardic effect of Fingolimod.
Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.
Immunosuppressants: May enhance the immunosuppressive effect of Fingolimod.
QTc-Prolonging Agents: QTc-Prolonging Agents may enhance the QTc-prolonging effect of QTc-Prolonging Agents.

03/13/2020 23:34:54 Fingolimod
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0